Having early and rapid access to research findings accelerates the pace of science and is paramount for advancing discovery. Springer Nature considers itself ideally placed to help facilitate this and making great research available as quickly as possible to the research community.
Gene therapy is about to achieve a milestone. Drug giant Novartis expects to win approval to launch what it says will be the first “blockbuster” gene-replacement treatment. A blockbuster is any drug with more than $1 billion in sales each year. The treatment, called Zolgensma, is able to save infants born with spinal muscular atrophy.
Do Swiss researchers share their data with other researchers and with the public? And if not, why? Which data repositories and other channels do they use for data sharing? A large-scale survey by the SNSF and swissuniversities offers some answers.
There has recently been a significant amount of media concern surrounding the poor mental health of academics. This extended paper sets out the scale of the problem and examines the factors which academics have identified as key causes of stress.
Language, cultural differences and expense are common downsides in some European countries, but researchers who land there love the opportunities to learn new techniques, work in a diverse setting and polish their confidence.
EPA Plan to End Funding for Children's Health Research Leaves Scientists Scrambling
Despite repeatedly expressing public support for children’s health, the U.S. Environmental Protection Agency (EPA) is ending funding for a network of research centers focused on environmental threats to kids, imperiling several long-running studies of pollutants’ effects on child development.
Agreement on Horizon Europe Creates a Chance to Ask What EU Research Policy is for - EuroScientist
Former EuroScience Secretary General Peter Tindemans, argues that it is good news that the European Parliament and European Council have reached a partial agreement on the contours of Horizon Europe, the next EU R&D programme.